Received Mar 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Twinrix late second dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 41-year-old female patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received 1st dose of vaccine on an unknown date). On 10-MAR-2025, the patient received the 2nd dose of Twinrix. On 10-MAR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 10-MAR-2025 The patient self-reported this case for himself/herself A patient reported that she had Twinrix later than she was supposed to because she did not get a notification from her facility at the time that it should be administered, which led to drug dose administration interval too long.